Last week, the firm launched AtheroGxOne the second of two cardiovascular next-gen sequencing panels, and hopes to launch its first liquid biopsy test in 2017.
The partners will develop panels to stratify patients with obesity and diabetes into surgical and alternate intervention groups in an upcoming clinical trial.
The New Jersey-based molecular diagnostics firm said it is planning to use the capital to "expand operations aggressively" and accelerate product development efforts.
NEW YORK (GenomeWeb News) – GeneWiz and Beijing ACCB Biotech today said they are collaborating on next-generation sequencing-based tests for the clinical market.
Science reports that a new White House Office of Management and Budget memo rescinds previous ones that helped research institutions deal with pandemic-related closures.
